HC Wainwright Has Negative Outlook of VIGL FY2026 Earnings

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright dropped their FY2026 earnings per share estimates for Vigil Neuroscience in a research report issued to clients and investors on Tuesday, May 27th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.84) per share for the year, down from their previous estimate of ($0.64). HC Wainwright has a "Neutral" rating and a $8.00 price objective on the stock. The consensus estimate for Vigil Neuroscience's current full-year earnings is ($2.07) per share. HC Wainwright also issued estimates for Vigil Neuroscience's FY2027 earnings at ($0.15) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $0.63 EPS.

A number of other research analysts also recently weighed in on VIGL. Citizens Jmp downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. JMP Securities reiterated a "market perform" rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. Mizuho lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. William Blair lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Jefferies Financial Group cut Vigil Neuroscience to a "hold" rating in a research report on Thursday, May 22nd. Ten research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Stock Up 0.2%

NASDAQ VIGL traded up $0.02 during trading hours on Thursday, reaching $7.91. 411,591 shares of the company were exchanged, compared to its average volume of 658,644. The stock has a market capitalization of $368.94 million, a P/E ratio of -3.84 and a beta of 1.90. Vigil Neuroscience has a 1 year low of $1.31 and a 1 year high of $7.95. The business's 50 day simple moving average is $2.79 and its 200-day simple moving average is $2.44.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04.

Institutional Investors Weigh In On Vigil Neuroscience

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC grew its position in shares of Vigil Neuroscience by 53.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after purchasing an additional 8,358 shares in the last quarter. Jane Street Group LLC purchased a new position in Vigil Neuroscience during the 4th quarter valued at about $83,000. Barclays PLC grew its holdings in Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after buying an additional 19,436 shares in the last quarter. Northern Trust Corp increased its position in shares of Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after buying an additional 14,572 shares during the period. Finally, Two Sigma Advisers LP lifted its holdings in shares of Vigil Neuroscience by 243.8% in the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after buying an additional 49,000 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.